Provided by Tiger Trade Technology Pte. Ltd.

Amgen

349.39
+1.170.34%
Post-market: 350.481.09+0.31%19:42 EDT
Volume:1.98M
Turnover:691.18M
Market Cap:188.14B
PE:24.55
High:351.25
Open:346.63
Low:346.60
Close:348.22
52wk High:391.29
52wk Low:261.43
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.83
T/O Rate:0.37%
Dividend:9.66
Dividend Rate:2.76%
EPS(TTM):14.23
EPS(LYR):14.23
ROE:106.10%
ROA:7.93%
PB:21.73
PE(LYR):24.55

Loading ...

BRIEF-OpenAI launches AI model GPT-Rosalind for life sciences research

Reuters
·
12 hours ago

OpenAI: Working With Customers Like Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific & Others to Apply Gpt-Rosalind Across Workflows

THOMSON REUTERS
·
12 hours ago

Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

TIPRANKS
·
Apr 15

Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story

Simply Wall St.
·
Apr 14

Zai Lab Shares Climb Over 3% Following Global Clinical Partnership with Amgen for Zoci Candidate

Stock News
·
Apr 14

Amgen Is Maintained at Buy by UBS

Dow Jones
·
Apr 14

UBS Adjusts Price Target on Amgen to $400 From $390, Maintains Buy Rating

MT Newswires Live
·
Apr 13

Amgen Inc : UBS Raises Target Price to $400 From $390

THOMSON REUTERS
·
Apr 13

ALX Oncology names Jeff Knight chief development and operating officer

Reuters
·
Apr 13

15 stocks to put on your list to buy when the market recovers

Dow Jones
·
Apr 12

This Startup's Psoriasis Drug Studies Have Lifted Its Stock -- Barrons.com

Dow Jones
·
Apr 11

Amgen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Apr 11

Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB)

Simply Wall St.
·
Apr 11

Amgen Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Apr 10

Amgen price target raised to $326 from $309 at Morgan Stanley

TIPRANKS
·
Apr 10

Amgen's Lung Cancer Therapy Tarlatamab Receives Approval in China

Deep News
·
Apr 10

Amgen's lung cancer drug tarlatamab wins China approval

Reuters
·
Apr 10

Amgen Is Maintained at Neutral by Guggenheim

Dow Jones
·
Apr 09

Guggenheim Adjusts Amgen Price Target to $351 From $347, Maintains Neutral Rating

MT Newswires Live
·
Apr 09

Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

TIPRANKS
·
Apr 09